
Danaher, Moderna, and Flag Ship Acquisition are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop, and commercialize biological therapies, pharmaceuticals, and diagnostic technologies. For investors, they tend to be high-risk, high-reward assets whose valuations hinge on scientific progress, clinical-trial results, regulatory approvals, patents, and partnership deals, often producing higher volatility than broader-market stocks. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read Our Latest Research Report on MRNA
Flag Ship Acquisition (ETHZ)
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
Read Our Latest Research Report on ETHZ
Featured Stories
- MarketBeat’s Top Five Stocks to Own in April 2026
- Here’s Why the AI Infrastructure Story Is Just Getting Bigger for GOOGL
- Allbirds Exits Shoes, Pivots to AI With NewBird Rebrand
- Game On: Wall Street’s New Rules and Your Money
- 2 Crypto Stocks Flashing Bullish Signals as Bitcoin Tops $75,000
- Up 775% in 5 Months, How Much Higher Can Syntec Optics Go?
